Sustainability in Isolation
Salon Today
SEPTEMBER 25, 2024
According to a new survey, many beauty professionals feel shy about discussing sustainability, and unable to act in the face of perceived opposition from other owners, colleagues and guests.
Wed.Sep 25, 2024
105 
Capella Bangkok name the No.1 in the World’s 50 Best Hotels 2024
Spa Executive
SEPTEMBER 25, 2024
Capella Bangkok offers panoramic views of the majestic Chao Phraya River and is a gateway to the eternal beauty of nature, and the urban oasis of the city. Bangkok has been named the No.1 Best Hotel in the World and Capella Singapore No.33 in the global ranking of The World’s 50 Best Hotels 2024. Capella Bangkok has also earned the title of The Best Hotel in Asia 2024.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Smart Snacking for Women Over 40: Balance Blood Sugar & Boost Energy During Menopause
Alison Bladh
SEPTEMBER 25, 2024
When we think about food, our attention often focuses on improving our main meals. But when you’re navigating the changes that come with perimenopause or menopause, it’s equally important to consider your snacks. The right snack choices can boost energy, balance blood sugar, and even support healthy weight management— all crucial for feeling your best during this stage of life.
A Comprehensive Guide to Effective Marketing Strategies for Your Skincare Business
The Skin Games
SEPTEMBER 25, 2024
Hey there, passionate esthetic business owners! thsi is aStacey Stark, Director of Marketing at Lexley Skincare and a marketing communications consultant with over two decades of experience. Today, I’m excited to dive deep into some game-changing marketing strategies that will help your small aesthetic business thrive and attract the clients you’ve always dreamed of serving.
The 5 Most Expensive States for Self-Care in the U.S.
Skin Inc
SEPTEMBER 25, 2024
To rank the most expensive cities for self-care, research conducted by Groupon found the average prices for six activities—brunch, massage, facial, iced latte, manicure and pedicure—across the 50 most populated U.S. cities.
Can You Shave Between Waxing?
Starpil Wax
SEPTEMBER 25, 2024
If you're new to waxing or just starting your waxing journey, you might be tempted to reach for a razor when you notice hair regrowth between sessions. However, it's crucial to understand that shaving between waxing is always a no-go and can significantly impact your waxing results. Table of Contents Reasons Not to Shave Between Waxes Benefits of Sticking to Your Waxing Schedule Benefits of Waxing vs.
Sign up to get articles personalized to your interests!
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
More Trending
1
Mindbody
SEPTEMBER 25, 2024
Our latest software improvements are here! We’ve streamlined branded web capabilities, optimized your business’s branded app, and more.
Get to Know Nadia Vassell: Beauty Launchpad 25 Under 50K Winner for 2024
Beauty Launchpad
SEPTEMBER 25, 2024
Meet Nadia Vassell (@nadiavassellsalon). She is a hairstylist, entrepreneur and owner of Nadia Vassell Salon in Soho, NY.
1
Mindbody
SEPTEMBER 25, 2024
The Customer Referral Program makes it easy to refer friends or local businesses in your community to Mindbody and earn $$$.
AbbVie Presents New Data on Efficacy of Upadacitinib in Moderate to Severe Atopic Dermatitis, High-Impact Areas
Dermatology Times
SEPTEMBER 25, 2024
A new analysis from phase 3 studies shows Rinvoq's effectiveness for moderate to severe AD with head and neck involvement.
Upadacitinib Performs Well in Phase 3 Trials of Hard-to-treat Head and Neck AD
The Dermatology Digest
SEPTEMBER 25, 2024
Upadacitinib (Rinvoq, AbbVie) performed well in moderate-to-severe atopic dermatitis (AD) patients with head and neck involvement, according to a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15mg or 30mg) in patients with moderate-to-severe atopic dermatitis (AD) stratified by the severity of disease in the head and neck region at baseline compared to placebo across 16 weeks.
Case-Based Insights: Managing Long-Standing Vitiligo With Extensive Depigmentation and Atopic Comorbidities
Dermatology Times
SEPTEMBER 25, 2024
Pearl E. Grimes, MD, provides case-based insights on managing long-standing vitiligo with extensive depigmentation and atopic comorbidities, focusing on treatment history, comorbid conditions, and the impact on quality of life.
Sun Pharma’s JAK Inhibitor Dims Anxiety and Depression Symptoms in AA
The Dermatology Digest
SEPTEMBER 25, 2024
Alopecia areata (AA) commonly travels with anxiety and depression, and new research shows that deuruxolitinib (Leqselvi, Sun Pharma) can improve symptoms of depression and anxiety in patients with AA. The US Food and Drug Administration (FDA) approved deuruxolitinib, a Janus kinase (JAK) 1/JAK 2 inhibitor, for adults with moderate to severe AA in July 2024.
Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies
Dermatology Times
SEPTEMBER 25, 2024
Pearl E. Grimes, MD, discusses strategies for optimizing vitiligo stabilization and repigmentation through combination therapies, emphasizing long-term maintenance, treatment modalities, and the use of topical agents like tacrolimus and ruxolitinib cream.
Orismilast Achieves Early itch Reduction in Adults With AD
The Dermatology Digest
SEPTEMBER 25, 2024
Orismilast demonstrated early itch reduction in adults with moderate-to-severe atopic dermatitis (AD), according to a phase 2b study presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam. Orismilast is a potent selective phosphodiesterase 4 (PDE4)-B and -D inhibitor under development by Union therapeutics.
Managing Long-Standing Vitiligo With Facial Involvement: Case-Based Insights Into OTC Solutions, Repigmentation, and Relapse Prevention
Dermatology Times
SEPTEMBER 25, 2024
Pearl E. Grimes, MD, explores managing long-standing vitiligo with facial involvement, focusing on over-the-counter solutions, repigmentation strategies, and relapse prevention techniques.
Fall into Shape with truSculpt Body Shaping in Brunswick, Ohio
Trillium Creek Dermatology
SEPTEMBER 25, 2024
As the crisp autumn air settles over Brunswick, Ohio, many residents are looking for ways to refine their figures before the holiday season arrives. At Trillium Creek Dermatology, we’re excited to offer a revolutionary body-shaping solution that’s perfect for the fall season: truSculpt body shaping. What is truSculpt? truSculpt is a non-invasive body contouring treatment that uses radiofrequency energy to target and eliminate stubborn fat cells.
Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm
Dermatology Times
SEPTEMBER 25, 2024
Pearl E. Grimes, MD, discusses the evolving treatment paradigm for vitiligo, highlighting the role of FDA-approved topical ruxolitinib and its impact on management strategies.
Seen Haircare Brand Closes $9 Million Series A Funding
The Dermatology Digest
SEPTEMBER 25, 2024
SEEN, the haircare brand developed by dermatologist Iris Rubin, MD, just closed a $9 million Series A funding. “This marks another transformative milestone for SEEN,” says Dr. Rubin in a news release. “A majority of adults in the U.S. have self-described sensitive skin and over 100 million people in the U.S. suffer from acne, eczema, dry scalp, and hair shedding, which can be exacerbated by irritating, allergenic, and/or pore-clogging ingredients in hair products.
Advancing Sexual Health Histories in Dermatology: A Modernized Comprehensive Approach for Diverse Populations
Dermatology Times
SEPTEMBER 25, 2024
In recent years, there has been a noticeable rise in diagnoses of sexually transmitted infections, often which present with skin findings.
Study Reports Long-Term Efficacy of Lebrikizumab for AD
Dermatology Times
SEPTEMBER 25, 2024
The study found that over 80% of patients who responded to lebrikizumab at week 16 maintained clear or almost-clear skin after 3 years.
Psoriasis within the US Hispanic Population: What Can Be Done to Diversify Clinical Data?
Dermatology Times
SEPTEMBER 25, 2024
Mona Shahriari, MD, FAAD, shared insights into prevalence, clinical presentations, increasing research diversity, and advocating for representation.
Study Results Demonstrate High Secukinumab Persistence in Psoriasis Patient Population of Greece
Dermatology Times
SEPTEMBER 25, 2024
Researchers presented interim 3-year results from the European SERENA study.
Let's personalize your content